We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Draft Regulation on ATMPs Excludes Nonviable Tissue-Engineered Products
New Draft Regulation on ATMPs Excludes Nonviable Tissue-Engineered Products
December 6, 2006
Tissue-engineered products "containing or made exclusively of nonviable human or animal tissues and/or cells, which do not act principally by pharmacological, immunological or metabolic action" would not be regulated as advanced therapy medicinal products (ATMPs) under the latest version of the European Commission's proposed ATMP regulation.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor